secwatch.observer — SEC 8-K summary
======================================

Issuer:     iTeos Therapeutics, Inc. (—)
CIK:        0001808865
Form:       8-K
Filed at:   2025-08-29T23:59:59+00:00
Accession:  0001193125-25-192031
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iTeos Therapeutics acquired by Concentra Biosciences for $10.047/sh plus CVR
----------------------------------------------------------------------------

- Tender offer closed with 72.17% of shares tendered; all conditions satisfied; merger effective Aug 29, 2025.
- Shareholders receive $10.047 cash per share plus one non-transferable CVR per share.
- CVR entitles holders to 80% of net proceeds from future disposition of specific product candidates (EOS-984, EOS-215, PTPN1/2 program) within 6-month disposition period.
- Board resigned; new directors/officers from Concentra (Kevin Tang CEO, Michael Hearne CFO, etc.).
- Company requests delisting from Nasdaq and intends to deregister with SEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/0001193125-25-192031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808865/000119312525192031/d938711d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-192031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer